Top 5 pediatric health headlines you missed in August 2025

Top 5 pediatric health headlines you missed in August 2025 | Image Credit: © sebra - stock.adobe.com.

August 2025 brought new insights and policy shifts with direct implications for pediatric prevention, infectious disease management, and early risk assessment.

In this monthly recap, Contemporary Pediatrics reviews the most significant developments shaping pediatric practice and public health. Click each title below for full coverage.

1. FDA pulls clearance of Pfizer-BioNTech COVID-19 vaccine for children under 5

On August 27, 2025, the FDA authorized updated COVID-19 vaccines for the 2025–2026 season while significantly restricting use in children. Pfizer’s Comirnaty is now approved only for adults 65 and older and individuals aged 5–64 with underlying conditions, while Moderna’s Spikevax remains available for high-risk children 6 months to 11 years and Novavax’s Nuvaxovid for at-risk patients 12 and older.

The American Academy of Pediatrics (AAP) criticized the move, warning that reduced pediatric access creates dangerous vulnerabilities as respiratory virus season approaches. The AAP reaffirmed its recommendation for vaccination beginning at 6 months and emphasized that decisions should remain between parents and pediatricians.

2. AAP updates guidance on screening for mental, emotional, and behavioral problems in children

The AAP issued updated guidance on screening for mental, emotional, and behavioral (MEB) problems in children, citing rising prevalence and gaps in detection. The report recommends caregiver depression screening in infancy, child MEB screening at 6, 12, 24, and 36 months, and annual screening after age 3.

Additional recommendations include yearly anxiety screening from ages 8–18, depression and suicide risk screening starting at age 12, and substance use assessments after age 11. The AAP emphasized use of validated tools, trauma-informed approaches, and integration of behavioral health services, while highlighting persistent barriers such as workforce shortages and disparities in access to care.

3. Omega-3 fatty acid intake linked to reduced risk of myopia in children

A diet high in omega-3 polyunsaturated fatty acids (PUFAs), mainly from fish oils, was linked to a lower risk of myopia in children, while high saturated fat intake was associated with increased risk, according to a study in the British Journal of Ophthalmology.

In an analysis of over 1000 Chinese children aged 6 to 8 years, those with higher omega-3 intake had shorter axial length and less myopic refraction, whereas higher saturated fat intake correlated with longer axial length and more myopic refraction. Researchers suggested that omega-3s may protect against myopia by improving ocular blood flow, though they emphasized that further longitudinal studies are needed to confirm causality.

4. Study findings link pediatric EoE treatment to reduced stiffening

Controlling inflammation in children with eosinophilic esophagitis (EoE) may prevent long-term complications, according to a longitudinal study from CHOP and Children’s Hospital Colorado published in Gastroenterology.

Among 112 pediatric patients, histologic remission was linked to improved esophageal distensibility, while lower baseline distensibility predicted higher risk of dysphagia, fibrostenosis, and need for stricture dilation. Investigators concluded that early and consistent treatment can reduce tissue remodeling and help identify patients who may benefit from more aggressive therapies.

5. AAP updates guidance on iatrogenic opioid dependence and withdrawal in children

The AAP released updated guidance on recognizing and managing opioid dependence and withdrawal in children prescribed opioids, published in Pediatrics.

The report highlights that physiologic dependence can develop after as few as 5 days of around-the-clock dosing and distinguishes this from opioid use disorder. Recommendations include tapering opioid therapy gradually, using validated withdrawal assessment tools such as WAT-1, and incorporating nonopioid analgesics and multidisciplinary support. The AAP emphasized structured, individualized tapering strategies to ensure safe withdrawal management in pediatric patients.